See more : H.G. Infra Engineering Limited (HGINFRA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Accelerate Diagnostics, Inc. (AXDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Accelerate Diagnostics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Polson Limited (POLSON.BO) Income Statement Analysis – Financial Results
- Société Générale Société anonyme (GLE.PA) Income Statement Analysis – Financial Results
- APT Medical Inc. (688617.SS) Income Statement Analysis – Financial Results
- FoxWayne Enterprises Acquisition Corp. (FOXWW) Income Statement Analysis – Financial Results
- Defence Therapeutics Inc. (DTC.CN) Income Statement Analysis – Financial Results
Accelerate Diagnostics, Inc. (AXDX)
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.06M | 12.75M | 11.78M | 11.17M | 9.30M | 5.67M | 4.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 475.52K | 183.13K | 212.70K | 502.11K | 118.61K | 850.57K | 653.98K | 855.66K | 1.57M | 2.90M | 7.38M | 2.50M | 2.10M |
| Cost of Revenue | 9.51M | 9.45M | 12.16M | 6.71M | 4.90M | 3.19M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.65K | 56.65K | 41.60K | 155.51K | 65.63K | 148.54K | 184.25K | 534.64K | 644.01K | 1.23M | 1.15M | 300.00K | 300.00K |
| Gross Profit | 2.55M | 3.30M | -381.00K | 4.46M | 4.40M | 2.48M | 3.18M | 246.00K | 147.00K | 122.00K | 48.29K | 236.00K | 1.12M | 2.25M | 1.27M | 465.87K | 126.48K | 171.10K | 346.60K | 52.98K | 702.03K | 469.73K | 321.02K | 923.38K | 1.67M | 6.23M | 2.20M | 1.80M |
| Gross Profit Ratio | 21.15% | 25.90% | -3.23% | 39.94% | 47.33% | 43.79% | 76.01% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 97.97% | 69.07% | 80.44% | 69.03% | 44.67% | 82.54% | 71.83% | 37.52% | 58.91% | 57.60% | 84.37% | 88.00% | 85.71% |
| Research & Development | 25.35M | 26.92M | 21.94M | 21.26M | 25.35M | 27.64M | 22.30M | 28.20M | 26.02M | 20.05M | 10.67M | 432.00K | 455.00K | 501.60K | 745.93K | 880.98K | 991.58K | 2.16M | 1.30M | 554.42K | 568.87K | 326.58K | 123.49K | 0.00 | 0.00 | 68.77K | 100.00K | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 2.95M | 810.08K | 869.35K | 919.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 709.01K | 1.53M | 997.83K | 956.67K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.32K | 9.62K | 1.40K | 13.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 288.86K | 817.35K | 1.20M | 1.29M | 0.00 | 0.00 |
| SG&A | 31.23M | 39.19M | 49.24M | 46.90M | 51.89M | 55.21M | 45.06M | 36.20M | 17.88M | 10.70M | 4.31M | 2.95M | 819.70K | 870.75K | 932.99K | 1.02M | 935.67K | 903.65K | 994.98K | 978.37K | 1.19M | 742.07K | 997.87K | 2.34M | 2.20M | 2.25M | 1.10M | 500.00K |
| Other Expenses | 0.00 | -227.00K | -20.00K | -60.00K | -14.00K | -28.00K | -184.00K | 2.35M | 1.79M | 888.00K | -4.45K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 293.11K | 490.02K | 170.38K | 638.43K | 895.80K | 0.00 | 0.00 | 200.00K | 100.00K |
| Operating Expenses | 56.58M | 66.11M | 71.18M | 68.16M | 77.23M | 82.85M | 67.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.19M | 2.24M | 3.38M | 2.61M | 1.83M | 2.25M | 1.24M | 1.76M | 3.24M | 2.20M | 2.32M | 1.40M | 600.00K |
| Cost & Expenses | 66.09M | 75.56M | 83.34M | 74.87M | 82.13M | 86.04M | 68.36M | 66.75M | 45.70M | 31.64M | 15.35M | 3.59M | 1.53M | 1.63M | 1.95M | 2.20M | 2.30M | 3.42M | 2.76M | 1.89M | 2.40M | 1.42M | 2.29M | 3.88M | 3.42M | 3.47M | 1.70M | 900.00K |
| Interest Income | 1.12M | 551.00K | 88.00K | 855.00K | 2.81M | 2.85M | 908.00K | 494.00K | 74.00K | 64.00K | 33.49K | 17.00K | 16.09K | 6.05K | 18.33K | 63.08K | 0.00 | 0.00 | 0.00 | 64.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.74M | 3.77M | 15.55M | 15.55M | 14.26M | 10.11M | 0.00 | 23.00K | 23.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.25M | 3.00M | 2.52M | 3.00M | 2.60M | 2.56M | 2.20M | 2.35M | 1.79M | 888.00K | 362.50K | 205.00K | 255.90K | 261.49K | 270.09K | 294.23K | 313.71K | 315.98K | 305.68K | 282.79K | 293.32K | 170.38K | 638.43K | 895.80K | 702.53K | 328.01K | 200.00K | 100.00K |
| EBITDA | -49.77M | -55.80M | -59.59M | -59.66M | -67.56M | -75.44M | -61.34M | -64.15M | -43.68M | -30.10M | -14.92M | -3.15M | -153.53K | 873.28K | -409.03K | -1.43M | -1.80M | -2.71M | -1.95M | -1.49M | -1.64M | -598.92K | -800.34K | -1.42M | 175.64K | 4.24M | 1.00M | 1.30M |
| EBITDA Ratio | -412.73% | -466.44% | -585.42% | -536.57% | -725.33% | -1,322.59% | -1,534.76% | -25,876.42% | -29,716.33% | -25,050.82% | -30,911.59% | -498.73% | -14.99% | 37.82% | -28.00% | -298.12% | -1,026.29% | -1,354.58% | -391.97% | -1,255.86% | -129.90% | -69.93% | 20.13% | -108.49% | 6.06% | 57.43% | 28.00% | 61.90% |
| Operating Income | -54.03M | -62.81M | -71.56M | -63.70M | -72.83M | -80.37M | -64.18M | -66.50M | -45.55M | -31.52M | -15.31M | -5.35M | -409.43K | 611.79K | -679.12K | -1.73M | -2.11M | -3.20M | -2.26M | -1.77M | -1.55M | -769.30K | -1.44M | -2.32M | -526.89K | 3.91M | 800.00K | 1.20M |
| Operating Income Ratio | -448.03% | -492.51% | -607.37% | -570.53% | -783.38% | -1,417.44% | -1,536.56% | -27,032.93% | -30,985.71% | -25,833.61% | -31,709.35% | -2,267.80% | -36.52% | 27.24% | -53.48% | -363.31% | -1,154.63% | -1,506.59% | -449.89% | -1,494.69% | -181.83% | -117.63% | -168.15% | -147.83% | -18.18% | 52.99% | 32.00% | 57.14% |
| Total Other Income/Expenses | -6.74M | 235.00K | -6.10M | -14.50M | -11.59M | -7.75M | 649.00K | 394.00K | 51.00K | -470.00K | 29.00K | 41.28K | 30.66K | 29.95K | -53.41K | 47.29K | 190.24K | 173.90K | 168.15K | 74.09K | 151.34K | 50.54K | -426.14K | 861.08K | 565.94K | 536.88K | 400.00K | -1.20M |
| Income Before Tax | -60.77M | -62.57M | -77.66M | -78.20M | -84.42M | -88.12M | -63.53M | -66.11M | -45.50M | -31.46M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -1.70M | -1.40M | -718.76K | -1.86M | -1.46M | 39.05K | 4.45M | 1.20M | 1.10M |
| Income Before Tax Ratio | -503.92% | -490.67% | -659.12% | -700.43% | -907.99% | -1,554.06% | -1,521.02% | -26,872.76% | -30,951.02% | -25,786.89% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -1,432.23% | -164.04% | -109.91% | -217.95% | -92.89% | 1.35% | 60.26% | 48.00% | 52.38% |
| Income Tax Expense | 850.00K | -77.00K | 45.00K | 5.00K | -111.00K | 211.00K | -651.00K | 267.00K | 74.00K | -527.00K | -22.13K | 1.96M | 378.76K | -641.75K | 714.20K | -47.29K | -190.24K | -173.90K | -168.15K | -789.40K | -19.43K | -318.03K | -318.19K | -533.46K | 31.38K | 1.57M | 200.00K | -1.10M |
| Net Income | -61.62M | -62.49M | -77.70M | -78.21M | -84.31M | -88.33M | -62.88M | -66.37M | -45.50M | -30.93M | -15.28M | -5.31M | -378.76K | 641.75K | -714.20K | -1.68M | -1.92M | -3.03M | -2.09M | -909.42K | -1.38M | -400.73K | -1.55M | -922.54K | 70.43K | 2.88M | 1.00M | 1.10M |
| Net Income Ratio | -510.97% | -490.06% | -659.50% | -700.47% | -906.80% | -1,557.78% | -1,505.43% | -26,981.30% | -30,951.02% | -25,354.92% | -31,649.21% | -2,250.42% | -33.78% | 28.58% | -56.24% | -353.37% | -1,050.75% | -1,424.83% | -416.40% | -766.71% | -161.75% | -61.28% | -180.76% | -58.86% | 2.43% | 39.00% | 40.00% | 52.38% |
| EPS | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.02 | -1.19 | 0.10 | 3.80 | 1.50 | 8.80 |
| EPS Diluted | -4.94 | -7.61 | -12.59 | -13.96 | -15.47 | -16.21 | -11.63 | -12.94 | -10.11 | -7.09 | -4.06 | -4.26 | -0.35 | 0.60 | -0.70 | -1.67 | -1.93 | -3.04 | -2.10 | -0.91 | -1.45 | -0.48 | -2.01 | -1.19 | 0.10 | 3.50 | 1.20 | 6.80 |
| Weighted Avg Shares Out | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 766.80K | 776.71K | 782.19K | 761.05K | 666.67K | 549.30K |
| Weighted Avg Shares Out (Dil) | 12.48M | 8.22M | 6.17M | 5.60M | 5.45M | 5.45M | 5.41M | 5.13M | 4.50M | 4.36M | 3.76M | 1.25M | 1.08M | 1.04M | 1.02M | 1.01M | 996.70K | 996.70K | 996.12K | 996.12K | 951.06K | 836.30K | 767.98K | 776.71K | 803.65K | 812.50K | 833.33K | 549.30K |
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.25 per share a year ago.
Accelerate Diagnostics Reports First Quarter 2023 Financial Results
TUCSON, Ariz. , May 11, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023.
Accelerate Diagnostics scheduled call to review 2023 first quarter results
TUCSON, Ariz. , April 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, May 11, 2023, at 4:30 p.m.
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).
Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?
Accelerate Diagnostics (AXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Accelerate Diagnostics, Inc. (AXDX) Q4 2022 Earnings Call Transcript
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Laura Pierson - IR Jack Phillips - President and CEO Steve Reichling - outgoing-CFO David Patience - incoming-CFO Conference Call Participants Alex...
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 12.50% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
TUCSON, Ariz. , March 29, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.
Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results
TUCSON, Ariz. , March 15, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 29, 2023, at 4:30 p.m.
Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement
TUCSON, Ariz. , March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023.
Source: https://incomestatements.info
Category: Stock Reports